指南与共识前列腺癌

前列腺癌基因检测指南:范围综述

Guidelines for genetic testing in prostate cancer: a scoping review.
指南 / 共识 · Prostate Cancer Prostatic Dis · 2023-05-18

本范围综述遵循PRISMA-ScR指南,检索电子数据库及灰色文献,纳入23部指南与共识声明。各指南普遍共识为转移性前列腺癌男性应接受基因检测,但局限期前列腺癌检测、检测对象与方法推荐差异较大,仍需进一步证据。

要点

  • 转移性前列腺癌男性接受基因检测在各指南与共识声明中具有普遍共识。
  • 局限期前列腺癌的基因检测共识较少,推荐存在差异。
  • 检测对象、检测方法及实施方面的推荐各不相同,缺乏共识。

核心结论

  • 前列腺癌基因检测虽被常规推荐且指南众多,但在检测对象与检测方法上仍存在相当大的共识缺乏。
  • 需要进一步证据以指导基于价值的基因检测策略在实践中的实施。

研究设计与样本

  • 范围综述,遵循PRISMA-ScR指南,检索电子数据库并手工检索灰色文献(包括关键组织网站)。
  • 采用人群、概念、背景(PCC)框架,纳入前列腺癌男性或高风险男性及其生物学家庭成员相关的现有指南与共识声明,不限地理区域。
  • 从660条引用中纳入23部符合标准的指南与共识声明。

主要发现

  • 基于关于检测对象与检测方法的不同证据水平,识别出多样化的推荐。
  • 各指南与共识声明普遍共识为转移性前列腺癌男性应接受基因检测。
  • 局限期前列腺癌的基因检测共识较少。
  • 在检测哪些基因方面存在一定共识,但检测对象、检测方法及实施方面的推荐存在差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Genetic testing, to identify pathogenic or likely pathogenic variants in prostate cancer, is valuable in guiding treatment decisions for men with prostate cancer and to inform cancer prevention and early detection options for their immediate blood relatives. There are various guidelines and consensus statements for genetic testing in prostate cancer. Our aim is to review genetic testing recommendations across current guidelines and consensus statements and the level of evidence supporting those recommendations. METHODS: A scoping review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-analyses extension for scoping review (PRISMA-ScR) guidelines. Electronic database searches and manual searches of grey literature, including websites of key organisations were conducted. Using the Population, Concept, Context (PCC) framework, this scoping review included: men with prostate cancer or men at high risk of prostate cancer and their biological families; existing guidelines and consensus statements with supporting evidence for genetic testing of men with prostate cancer from any geographical location worldwide. RESULTS: Of the 660 citations identified, 23 guidelines and consensus statements met the inclusion criteria for the scoping review. Based on different levels of evidence about who should be tested and how, a diverse range of recommendations were identified. There was general consensus among the guidelines and consensus statements that men with metastatic disease be offered genetic testing; however, there was less consensus in relation to genetic testing in localised prostate cancer. While there was some consensus in relation to which genes to test, recommendations varied regarding who to test, testing methods and implementation. CONCLUSION: While genetic testing in prostate cancer is routinely recommended and numerous guidelines exist, there is still considerable lack of consensus regarding who should be tested and how they should be tested. Further evidence is needed to inform value-based genetic testing strategies for implementation in practice.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Tuffaha H, Edmunds K, Fairbairn D, et al. Guidelines for genetic testing in prostate cancer: a scoping review. Prostate Cancer Prostatic Dis. 2023. PMID: 37202470. doi:10.1038/s41391-023-00676-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。